| Therapeutic Area |
Phase |
Country |
Patient Enrolled |
Therapeutic Indication |
Partner &Sponsor |
| Cardiovascular |
III |
Ireland and UK |
Set up of 12 UK and Irish sites including all regulatory and Ethics applications up to and including Initiation of all Sites |
Symptomatic left ventricular systolic dysfunction and anaemia |
Multinational Pharmaceutical |
| Renal (Transplant) |
III |
5 sites in UK & Ireland |
6 |
First-line immunosuppression |
Multinational Pharmaceutical |
| Gastrointestinal |
IV |
40 sites in Ireland & UK |
857 |
Gastro-esophageal reflux disease |
Multinational Pharmaceutical |
| Cardiovascular |
III |
10+ sites in the UK |
50+ |
Inadequate blood pressure |
Multinational Pharmaceutical |
| Oncology |
II |
10 sites in the UK |
Enrolled 25+ |
Metastatic colorectal cancer |
Multinational Pharmaceutical |
| Diabetes |
I |
Ireland |
12 |
Insulin dependent diabetes mellitus |
Bio Technology |
| Oncology |
III |
UK |
Set up of study at 3 sites in UK |
fully resected stage III colon cancer |
Bio Technology |
| Gastrointestinal |
III |
50+ sites in Ireland, UK. France, Spain, Czech Republic, Germany, Belguim |
Enrolled: 2000+ |
clostridium-difficile associated diarrhea |
Multinational Bio Technology |
| Rheumatology |
III |
UK, France, Belguim, Germany, Czech Republic |
300 |
Symptomatic osteoarthritis of the knee |
Multinational Bio Technology |
| Neurology |
II |
Ireland, UK |
30+ |
mild to moderate Alzheimer disease |
Multinational Pharmaceutical |
| Dermatology |
IV |
25 sites in Ireland |
50+ |
primary and secondary skin and soft tissue infections |
Multinational Pharmaceutical |
| Rheumatology |
III |
Ireland |
24 |
bone turnover in postmenopausal women |
National Bio Technology |
| Human parasitology |
III |
Ireland |
300+ |
Head lice |
Multinational Pharmaceutical partnership |
| Oncology |
III |
Ireland and UK |
15+ |
relapsed/refractory multiple myeloma |
Multinational Pharmaceutical |
| Oncology |
III |
Ireland |
Just commenced |
metastatic, castration-resistant prostate cancer |
Multinational Pharmaceutical |
| Nephrology |
III |
UK |
Study start up only |
chronic kidney disease in children |
Multinational Pharmaceutical |
| Cardiovascular |
III |
Ireland |
20+ |
Left ventricular dysfunction after acute myocardial infraction |
Multinational Pharmaceutical |
| Oncology |
Expanded Access Program |
United Kingdom, Ireland |
40+ (ongoing) |
ERBB2 Over-expressing Locally Advanced or Metastatic Breast Cancer |
Multinational Pharmaceutical |
| Oncology |
EAP |
Ireland |
5+ |
Patients with cytokine-refractory metastatic renal cell carcinoma |
Multinational Pharmaceutical |
| Rheumatology |
III |
Ireland |
20+ |
Fibromyalgia |
Multinational Pharmaceutical |
| Psychiatry |
IIIb |
Ireland |
20+ |
DSM-IV Generalized Anxiety disorder in outpatients |
Multinational Pharmaceutical |
| Gastrointestinal |
III |
Ireland |
12 |
colorectal sporadic adenomatous polyps |
Multinational Pharmaceutical |
| Oncology |
II |
UK |
Study set up only |
Patients with Metastatic Solid Tumors on Chemotherapy |
Multinational Bio Technology |
| Oncology |
III |
UK |
20+ |
Multiple Myeloma |
Multinational Pharmaceutical |
| Oncology |
III |
UK |
Study start up only |
Malignant Pigmented Nevi & Histological Diagnoses |
Virtual Pharmaceutical |
| Oncology |
III |
Ireland |
Ongoing |
Previously Treated Metastatic Colorectal Cancer |
Multinational Bio Tech |
| Oncology |
III |
Ireland |
Ongoing |
patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck |
Multinational Bio Tech |
| Oncology |
III |
Ireland |
Ongoing |
Non-small Cell Lung Cancer |
Multinational Bio Tech |
| Oncology |
III |
Ireland |
currently ongoing |
Non-small Cell Lung Cancer already receiving gencitabine and platinum |
Multinational Bio Tech |
| Cardiology |
III |
Over 100 primary care sites in Ireland and the UK |
500+ currently ongoing |
Prevention of Cardiovascular Disease Events |
Multinational Pharmaceutical |
| Respiratory |
II |
UK |
30+ (Ongoing) |
Allergic Rhinitis |
High Potential University Start-up Bio Tech |
| Burns (Plastic Surgery) |
III |
UK |
20+ Currently ongoing |
Burns Patients (children & adults) |
High Potential University Start-up Bio Tech |
